StemCells, Inc. (NASDAQ:STEM)

CAPS Rating: 2 out of 5

A biopharmaceutical company that operates in one segment, the development of novel cell-based therapeutics designed to treat human diseases and disorders.


Player Avatar charlitobandito (< 20) Submitted: 1/27/2009 8:49:30 PM : Outperform Start Price: $25.70 STEM Score: -239.71

Government funding and subsidizing. The bill will go through anyday now. Still a buy... lots of money to be made in this industry. This stock had its feet kicked out from under it this morning because of people pocketing profits The sell-off has not real substance. Great time to stock up. The reason these stem cell stocks are so low involves low cash levels, which is a problem but the funding should fix that. All I can say is buy or hold, because the month after Congress passes that bill you will see these reach 10+ and still be rising.

Featured Broker Partners